Chelsea Therapeutics International is a development stage pharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products. Co. is developing Northera™ (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension in patients with primary autonomic failure (Parkinson's disease, multiple system atrophy and pure autonomic failure), dopamine-?-hydroxylase deficiency and non-diabetic autonomic neuropathy. In addition to droxidopa, Co. has a portfolio of metabolically inert antifolates that it has studied as a potential treatment of rheumatoid arthritis.